MDT Stock Recent News
MDT LATEST HEADLINES
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Wells Fargo analysts raised their price target for shares of the medical-technology company to $100 from $77.
"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 67 Aristocrats, screened as of April 5, 2023, represented all eleven Morningstar Sectors. Broker estimated top ten net gains ranged from 14.14%-42.97% topped by SWK & VFC.
In these tumultuous times, with markets facing substantial headwinds from yet another financial crisis, savvy investors are on the lookout for safe havens. Perhaps the best refuge is in undervalued dividend stocks, particularly those trading at significant discounts compared to their sector peers.
Medtronic and ExxonMobil are two top dividend stocks that have been raising their payouts for 40-plus years. Medtronic's business should pick up this year now that China has abandoned its restrictive COVID lockdowns.
The world's largest medical device maker Medtronic PLC (NYSE: MDT) stock has fallen since April 2022. However, shares may have bottomed out.
Geoffrey Martha, Medtronic CEO, joins 'TechCheck' to discuss future of the company and his outlook for 2023.
Medtronic plc (NYSE:MDT ) J.P. Morgan 41st Annual Healthcare Conference January 9, 2023 11:15 AM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Que Dallara - Executive Vice President and President, Diabetes Operating Unit Sean Salmon - Executive Vice President and President, Cardiovascular Portfolio Conference Call Participants Robbie Marcus - J.P.
Medtronic plc is a well-established medical devices company with a diverse range of products and a strong track record of financial performance. Medtronic operates in business segments that are well-positioned for the future.
Medtronic investors have suffered a massive battering as MDT moves closer to its COVID lows. The company's headwinds are likely still manifesting, worsened by macroeconomic challenges.